Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer

被引:16
|
作者
Cao, Sheng [1 ,2 ]
Li, Yang [1 ,3 ]
Li, Jin [4 ,5 ]
Li, Chang-Fei [1 ]
Zhang, Wei [6 ]
Yang, Zeng-Qi [2 ]
Meng, Song-Dong [1 ]
机构
[1] Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China
[2] NW A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China
[3] Sichuan Normal Univ, Coll Life Sci, Chengdu 610066, Peoples R China
[4] Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100191, Peoples R China
[5] Beijing Tiantan Biol Prod Co Ltd, Beijing 100024, Peoples R China
[6] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100021, Peoples R China
关键词
HER2; overexpression; confocal microscopy assay; circulating tumor cells; quantitative measurement; CIRCULATING TUMOR-CELLS; RESISTANT PROSTATE-CANCER; POLYMERASE-CHAIN-REACTION; BONE-MARROW; PERIPHERAL-BLOOD; GENE STATUS; IMMUNOFLUORESCENCE; THERAPY;
D O I
10.3892/or_00000651
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HER2 analysis in circulating tumor cells (CTCs) may have clinical significance for HER2-targeted therapy as HER2-positive CTCs and disseminated tumor cells can be detected in patients with HER2-negative primary tumors who currently do not have access to HER2-targeted therapy. In this study, we performed quantitative analysis by confocal microscopy assay for evaluation of HER2 expression in individual tumor cells. HER2 testing by confocal microscopy assay exhibited high concordance with results of real-time PCR, Western blot analysis and FISH analysis. We found that there was a significant positive correlation between HER2 overexpression and gene amplification in individual CTCs, which provided validation of confocal microscopy assay for HER2 expression in CTCs. By using subsets of 10 consecutive cells (bins), we conclude that HER2 expression (3+) in CTCs predicts HER2 overexpression of tumor with high probability in breast cancer patients. These results may provide interpretive guidelines for HER2 status assay in CTCs and raise great opportunities for using CTCs as non-invasive and 'real-time' biopsy to examine and monitor the status of tumor markers.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 50 条
  • [21] HER2 Dual ISH Determination of HER2 Gene Status in Breast Cancer: Interobserver Reproducibility
    Limbach, A. A. Lott
    Downs-Kelly, E. P.
    Papouchado, B. G.
    Tubbs, R. R.
    Lanigan, C.
    Booth, C. N.
    LABORATORY INVESTIGATION, 2012, 92 : 52A - 52A
  • [22] HER2 Dual ISH Determination of HER2 Gene Status in Breast Cancer: Interobserver Reproducibility
    Limbach, A. A. Lott
    Downs-Kelly, E. P.
    Papouchado, B. G.
    Tubbs, R. R.
    Lanigan, C.
    Booth, C. N.
    MODERN PATHOLOGY, 2012, 25 : 52A - 52A
  • [23] Her2 expression in matched metastatic tumor and circulating tumor cells (ctcs) in breast cancer: Implications for profiling and monitoring of her2 status to help guide anti-her2 therapy
    Stearns, Vered
    Lehman, Jennifer
    Mitchell, Christine
    Blouw, Barbara
    Huynh, Lan
    Singh, Veena
    CANCER RESEARCH, 2021, 81 (04)
  • [24] Enabling HER2 and androgen receptor (AR) protein expression and localization in circulating tumor cells (CTCs) of ER(+/-)HER2(-) metastatic breast cancer (MBC) patients (pts)
    Ontiveros, P.
    Landaverde, C.
    Graf, R.
    Levin, M. K.
    Hippely, S.
    Wang, Y.
    Landers, M.
    Dittamore, R.
    O'Shaughnessy, J. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [25] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [26] ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
    Isabel Pinhel
    Margaret Hills
    Suzanne Drury
    Janine Salter
    Georges Sumo
    Roger A'Hern
    Judith M Bliss
    Ivana Sestak
    Jack Cuzick
    Peter Barrett-Lee
    Adrian Harris
    Mitch Dowsett
    Breast Cancer Research, 14
  • [27] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [28] ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
    Pinhel, Isabel
    Hills, Margaret
    Drury, Suzanne
    Salter, Janine
    Sumo, Georges
    A'Hern, Roger
    Bliss, Judith M.
    Sestak, Ivana
    Cuzick, Jack
    Barrett-Lee, Peter
    Harris, Adrian
    Dowsett, Mitch
    BREAST CANCER RESEARCH, 2012, 14 (02)
  • [29] Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay
    Huang, Weidong
    Reinholz, Monica
    Weidler, Jodi
    Lie, Yolanda
    Paquet, Agnes
    Whitcomb, Jeannette
    Lingle, Wilma
    Jenkins, Robert B.
    Chen, Beiyun
    Larson, Jeffrey S.
    Tan, Yuping
    Sherwood, Thomas
    Bates, Michael
    Perez, Edith A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (02) : 303 - 311
  • [30] High agreement between whole slide imaging and optical microscopy for assessment of HER2 expression in breast cancer Whole slide imaging for the assessment of HER2 expression
    Nunes, Cristiana
    Rocha, Rafael
    Buzelin, Marcelo
    Balabram, Debora
    Foureaux, Fernanda
    Porto, Simone
    Gobbi, Helenice
    PATHOLOGY RESEARCH AND PRACTICE, 2014, 210 (11) : 713 - 718